1h Free Analyst Time
The publisher has been monitoring the canine atopic dermatitis market and it is poised to grow by $319.37 mn during 2022-2026, progressing at a CAGR of 7.75% during the forecast period. The report on the canine atopic dermatitis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in pet humanization and rising awareness about disease prevention and pet insurance.
The canine atopic dermatitis market analysis includes the product segment and geographic landscape.
The canine atopic dermatitis market is segmented as below:
By Product
- Antihistamines
- Glucocorticoids
- Progestational compounds
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the rising importance of treatment of allergic conditions in animals as one of the prime reasons driving the canine atopic dermatitis market growth during the next few years.
The report on canine atopic dermatitis market covers the following areas:
- Canine atopic dermatitis market sizing
- Canine atopic dermatitis market forecast
- Canine atopic dermatitis market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading canine atopic dermatitis market vendors that include Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc. Also, the canine atopic dermatitis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
- Research and development (R&D) and drug discovery
- Integration and product development
- Manufacturing
- Outbound logistics
- Marketing and sales
- Support services
- Innovation
Market Sizing
- Market segment analysis
- Market size 2021
- Market definition
- Market outlook: Forecast for 2021 - 2026
- Estimating growth rates for emerging and high-growth markets
- Estimating growth rates for mature markets
Five Forces Analysis
- Five Forces Summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Antihistamines - Market size and forecast 2021-2026
- Glucocorticoids - Market size and forecast 2021-2026
- Progestational compounds - Market size and forecast 2021-2026
- Others - Market size and forecast 2021-2026
- Market opportunity by Product
Customer landscape
- Overview
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- Asia - Market size and forecast 2021-2026
- ROW - Market size and forecast 2021-2026
- Key leading countries
- Market opportunity By Geographical Landscape
Drivers, Challenges, and Trends
- Market drivers
- Increase in pet humanization
- Rising awareness about disease prevention and pet insurance
- Rising importance of treatment of allergic conditions in animals
- Market challenges
- Stringent global regulatory requirements
- Poor patient adherence
- Increasing resistance for antibiotics
- Market trends
- Increase in M&A
- Increasing drug administration in livestock to propel drugs
- Rising number of veterinary drug stores
Vendor Landscape
- Overview
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Bioceltix Spolka Akcyjna
- Ceva Sante Animale
- Dechra Pharmaceuticals Plc
- Elanco Animal Health Inc.
- Novartis AG
- Toray Industries Inc.
- Vetoquinol UK Ltd.
- Vimian Group AB
- Virbac
- Zoetis Inc.
Appendix
- Scope of the report
- Market definition
- Objectives
- Notes and Caveats
- Currency conversion rates for US$
- Research Methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2021 - 2026 ($ million)
- Global market: Year-over-year growth 2021 - 2026 (%)
- Five forces analysis 2021 & 2026
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2021
- Product - Market share 2021-2026 (%)
- Comparison by Product
- Antihistamines - Market size and forecast 2021-2026 ($ million)
- Antihistamines - Year-over-year growth 2021-2026 (%)
- Glucocorticoids - Market size and forecast 2021-2026 ($ million)
- Glucocorticoids - Year-over-year growth 2021-2026 (%)
- Progestational compounds - Market size and forecast 2021-2026 ($ million)
- Progestational compounds - Year-over-year growth 2021-2026 (%)
- Others - Market size and forecast 2021-2026 ($ million)
- Others - Year-over-year growth 2021-2026 (%)
- Market opportunity by Product
- Customer landscape
- Market share By Geographical Landscape 2021-2026 (%)
- Geographic comparison
- North America - Market size and forecast 2021-2026 ($ million)
- North America - Year-over-year growth 2021-2026 (%)
- Europe - Market size and forecast 2021-2026 ($ million)
- Europe - Year-over-year growth 2021-2026 (%)
- Asia - Market size and forecast 2021-2026 ($ million)
- Asia - Year-over-year growth 2021-2026 (%)
- ROW - Market size and forecast 2021-2026 ($ million)
- ROW - Year-over-year growth 2021-2026 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Bioceltix Spolka Akcyjna - Overview
- Bioceltix Spolka Akcyjna - Product and service
- Bioceltix Spolka Akcyjna - Key offerings
- Bioceltix Spolka Akcyjna - Key customers
- Bioceltix Spolka Akcyjna - Segment focus
- Ceva Sante Animale - Overview
- Ceva Sante Animale - Product and service
- Ceva Sante Animale - Key offerings
- Ceva Sante Animale - Key customers
- Ceva Sante Animale - Segment focus
- Dechra Pharmaceuticals Plc - Overview
- Dechra Pharmaceuticals Plc - Business segments
- Dechra Pharmaceuticals Plc - Key offerings
- Dechra Pharmaceuticals Plc - Key customers
- Dechra Pharmaceuticals Plc - Segment focus
- Elanco Animal Health Inc. - Overview
- Elanco Animal Health Inc. - Product and service
- Elanco Animal Health Inc. - Key offerings
- Elanco Animal Health Inc. - Key customers
- Elanco Animal Health Inc. - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Toray Industries Inc. - Overview
- Toray Industries Inc. - Business segments
- Toray Industries Inc. - Key offerings
- Toray Industries Inc. - Key customers
- Toray Industries Inc. - Segment focus
- Vetoquinol UK Ltd. - Overview
- Vetoquinol UK Ltd. - Product and service
- Vetoquinol UK Ltd. - Key offerings
- Vetoquinol UK Ltd. - Key customers
- Vetoquinol UK Ltd. - Segment focus
- Vimian Group AB - Overview
- Vimian Group AB - Product and service
- Vimian Group AB - Key offerings
- Vimian Group AB - Key customers
- Vimian Group AB - Segment focus
- Virbac - Overview
- Virbac - Business segments
- Virbac - Key offerings
- Virbac - Key customers
- Virbac - Segment focus
- Zoetis Inc. - Overview
- Zoetis Inc. - Business segments
- Zoetis Inc. - Key offerings
- Zoetis Inc. - Key customers
- Zoetis Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global canine atopic dermatitis market: Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising importance of treatment of allergic conditions in animals."
According to the report, one of the major drivers for this market is the increase in pet humanization.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bioceltix Spolka Akcyjna
- Ceva Sante Animale
- Dechra Pharmaceuticals Plc
- Elanco Animal Health Inc.
- Novartis AG
- Toray Industries Inc.
- Vetoquinol UK Ltd.
- Vimian Group AB
- Virbac
- Zoetis Inc.
